Deb Geraghty, PhD, MBA

Vice President, Commercial & Portfolio Strategy
Dimension Therapeutics, Inc.

deb geraghty

Deb Geraghty brings broad expertise in science, business and strategy across the biopharmaceutical and consulting industries. Dr. Geraghty currently works in an advisory capacity with pharmaceutical, biotech and non-profit organizations.  Dr. Geraghty is the Vice President of Commercial and Portfolio Strategy for Dimension Therapeutics, Inc.

Prior to this, Dr. Geraghty was Vice President and Founder of Cydan Development, Inc., an orphan drug accelerator that identifies and de-risks early-stage programs with therapeutic and commercial potential. A member of the founding team, Cydan raised $26M in series A funding, focused on the lives of patients with rare diseases. Previously, Dr. Geraghty was Head, Portfolio Advancement at Aileron Therapeutics where she led strategic growth and commercial efforts, and was Director, New Product Marketing at Infinity Pharmaceuticals, building the commercial team and serving as commercial lead on four clinical programs.

Earlier, Dr. Geraghty founded Back Bay Strategies, and worked at Kendall Strategies, Feinstein Kean Healthcare and Genzyme Corporation. Dr. Geraghty serves on the Board at Emma Willard School.

Dr. Geraghty earned a BS in Biology at Union College, an MBA from the Carroll School at Boston College, and a PhD in Molecular Biology at the University of Vermont.